Chloroquine Sulfate

DRUG4 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Institut Pasteur, Cambodia, Washington University School of Medicine, UMC Utrecht

Conditions

COVID-19Coronavirus InfectionMalariaPlasmodium Falciparum MalariaVivax Malaria

Phase 3

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

TerminatedNCT04341727

Washington University School of MedicineCoronavirus Infection

Start: 2020-04-04End: 2021-04-01Updated: 2024-04-25

Phase 4

CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi

CompletedNCT00125489

National Institute of Allergy and Infectious Diseases (NIAID)Malaria, Plasmodium Falciparum Malaria

Start: 2005-05-31End: 2005-12-31Target: 210Updated: 2010-08-27

Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:

CompletedNCT02118090

Institut Pasteur, CambodiaVivax Malaria

Start: 2014-05-31End: 2015-03-31Updated: 2015-03-24

Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19

TerminatedNCT04362332

UMC UtrechtCOVID-19

Start: 2020-04-14End: 2020-06-08Updated: 2020-06-19

Related Papers

Genomic Analyses Reveal the Common Occurrence and Complexity of <i>Plasmodium vivax</i> Relapses in Cambodia

mBio2018-01-2262 citations